Absence of TIMP4 ameliorated high-fat-diet-induced obesity in mice 30
Food and Drug Administration (FDA) has approved Eli Lilly and Company's ZepboundTM (tirzepatide) injection, marking it as the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors
And since then weve gone absolute gangbusters, with listings in Sprouts, Erewhon and Bristol Farms and other significant retail launches coming up as well. Unusually for a brand of this size, Washington also has a human clinical study showing volunteers with type 2 diabetes consuming Supergut products demonstrated improved glycemic control and a small reduction in body weight in a 12-week study
Lipid peroxidation products like 4-HNE form covalent adducts with cysteine residues in the insulin receptor -subunit, reducing its tyrosine kinase activity by up to 60% (Regina and Tong, 2025)
District Judge Karen Marston in Philadelphia, who also oversees the existing GLP-1 drug litigation
Natalie S
.jpg)
